GUTSFractyl Health, Inc.
What is the market doing?
In an uptrend. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
In an uptrend, above its rising 50- and 200-day averages. Overbought (RSI 87). Price is +368% vs its 200-day average.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How GUTS is trading
Fractyl Health, Inc. is −50% over the past year while the S&P 500 is +18%: 68 points behind the market. Through the fall, its own insiders bought $127K more stock than they sold.
1-year return · S&P 500 +18%
- vs 200-day average
- +368%
vs 200-day average · a clear uptrend
- RSI (14)
- 87
RSI (14) · overbought, bought harder than it has been sold
- Below its 52-week high
- 8.3%
Below its 52-week high
Details›
- Last close2026-10-08
- $0.49
- 1 monthS&P 500 +1.6%
- −33%
- 1 yearS&P 500 +18%
- −50%
- vs 50-day average$0.95
- +343%
- 52-week high
- $4.58
- 52-week low
- $0.39
- Annualised volatility
- 736%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-08
- $127K
| Year | Return |
|---|---|
| 2026 (year to date) | +91% |
| 2025 | +6.8% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 2 | 0 of 2 | −45% |
| Feb | 2 | 1 of 2 | −6.6% |
| Mar | 3 | 0 of 3 | −15% |
| Apr | 3 | 2 of 3 | +12% |
| May | 3 | 2 of 3 | +25% |
| Jun | 3 | 0 of 3 | −18% |
| Jul | 3 | 1 of 3 | −8.2% |
| Aug | 3 | 2 of 3 | −12% |
| Sep | 3 | 1 of 3 | +3.9% |
| Oct | 3 | 2 of 3 | +223% |
| Nov | 2 | 1 of 2 | +9.3% |
| Dec | 2 | 1 of 2 | +10% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Biotechnology
The closest names by size in the same industry